Linnaeus Therapeutics, Inc., a Penn spinout clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts. Based on promising preliminary safety, pharmacodynamic and efficacy data, this expanded agreement will allow the companies to further evaluate the combination of LNS8801 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors. Read More
